BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today announced today that Leqembi® (generic name: lecanemab) has been launched in South Korea. Leqembi received approval in South Korea ...
Fintica AI Ltd, a leading innovator in next-generation AI solutions for capital markets, and Legend Arb Trading Limited, a Hong Kong-based proprietary trading firm with a global footprint across major ...
at 19:31 "LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea Eisai Co., Ltd.
Eisai (ESAIY) and Biogen (BIIB) announced that the humanized anti-soluble aggregated amyloid-beta, or Abeta, monoclonal antibody Leqembi has been launched in South Korea. Leqembi received the Ministry ...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...
We recently compiled a list of the 10 Worst Performing Healthcare Stocks in 2024. In this article, we are going to take a ...
Two significant legal decisions have come or are coming into force over the next couple of weeks in the UK and Europe.
November is National Alzheimer’s Awareness Month.The Alliance for Aging Research is using this month to raise awareness about ...
Buoyed by a strong performance in its core private hospital business and a surge in sales of its tracer drug NeuraCeq, Life ...
Eisai and the National Center of Neurology and Psychiatry in Tokyo will study the link between APOE genotype and safety and efficacy of Leqembi.
The European Medicines Agency (EMA) has recommended market approval for Alzheimer’s antibody Leqembi (lecanemab), reversing ...